Xu Jiawen, Yang Wenlin, Wang Qiangxiu, Zhang Qinghui, Li Xungeng, Lin Xiaoyan, Liu Xiuping, Qin Yejun
Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250021, Shandong, China.
Department of Pathology, Shanghai Medical College, Fudan University Shanghai 200032, China.
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7915-22. eCollection 2014.
Downregulation of hepatocellular carcinoma related protein 1 (HCRP1) has been reported to be associated with a poor prognosis in a variety of malignant tumors. The purpose of this study was to assess HCRP1 expression in breast cancer and to examine its possible correlation with commonly used prognostic factors, particularly epidermal growth factor receptor (EGFR).
Immunohistochemical analysis was performed on tumors from 194 patients with primary breast cancer. HCRP1 expression was analyzed along with major clinicopathological variables.
HCRP1 protein expression was shown to be correlated with age (P = 0.001), histological grade (P = 0.005), tumor progression (P = 0.013), and death (P = 0.001), but not with tumor size, lymph-node metastasis, or Ki67 status. Kaplan-Meier survival curves showed that lower HCRP1 expression was significantly correlated with increased short-term survival (P < 0.001), and both univariate and multivariate analyses revealed that HCRP1, tumor size, lymph-node metastasis, and human epidermal growth factor receptor-2 (HER-2) were independent prognostic factors (all P < 0.05). In addition, low HCRP1 expression was much more frequent in triple negative breast cancer (TNBC; 63.89%) than in luminal (16.95%) and HER-2 overexpression phenotypes (7.5%; P < 0.001), and significant correlations between HCRP1 and survival time were observed for the TNBC group (P < 0.004). Furthermore, an inverse relationship between HCRP1 and EGFR expression was found both for the complete set of all cases (P < 0.001), and for each phenotype analyzed individually (P < 0.05).
Our results suggest that HCRP1 may play an important role in EGFR regulation and that its decreased expression is an independent predictor of breast cancer, especially in TNBC patients.
据报道，肝细胞癌相关蛋白1（HCRP1）的下调与多种恶性肿瘤的不良预后相关。本研究的目的是评估HCRP1在乳腺癌中的表达，并探讨其与常用预后因素，特别是表皮生长因子受体（EGFR）的可能相关性。
对194例原发性乳腺癌患者的肿瘤进行免疫组织化学分析。分析HCRP1表达以及主要临床病理变量。
HCRP1蛋白表达与年龄（P = 0.001）、组织学分级（P = 0.005）、肿瘤进展（P = 0.013）和死亡（P = 0.001）相关，但与肿瘤大小、淋巴结转移或Ki67状态无关。Kaplan-Meier生存曲线显示，较低的HCRP1表达与短期生存率增加显著相关（P < 0.001），单因素和多因素分析均显示HCRP1、肿瘤大小、淋巴结转移和人表皮生长因子受体2（HER-2）是独立的预后因素（所有P < 0.05）。此外，三阴性乳腺癌（TNBC；63.89%）中低HCRP1表达比管腔型（16.95%）和HER-2过表达型（7.5%）更常见（P < 0.001），TNBC组中观察到HCRP1与生存时间之间存在显著相关性（P < 0.004）。此外，在所有病例的完整组中（P < 0.001）以及对每个单独分析的表型中（P < 0.05），均发现HCRP1与EGFR表达呈负相关。
我们的结果表明，HCRP1可能在EGFR调节中起重要作用，其表达降低是乳腺癌的独立预测指标，尤其是在TNBC患者中。
